FDA Greenlights Stem Cells Trial Aiming to Improve Quality of Life

FDA Greenlights Stem Cells Trial Aiming to Improve Quality of Life

300895

FDA Greenlights Stem Cells Trial Aiming to Improve Quality of Life

The U.S. Food and Drug Administration (FDA) has given the green light to a Phase 2 clinical trial that will assess the efficacy of using adult mesenchymal stem cells (MSCs) to treat the symptoms of mild to moderate multiple sclerosis (MS). The non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF), which received the FDA authorization, believes such stem cell treatments may work to improve the quality of life of people with the neurodegenerative disease. “Current treatments for MS…

You must be logged in to read/download the full post.